Investment House LLC boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 6.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,785 shares of the biopharmaceutical company’s stock after purchasing an additional 2,760 shares during the period. Investment House LLC’s holdings in Emergent BioSolutions were worth $4,192,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC boosted its position in Emergent BioSolutions by 17.5% during the third quarter. Commonwealth Equity Services LLC now owns 11,556 shares of the biopharmaceutical company’s stock valued at $1,194,000 after purchasing an additional 1,724 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in Emergent BioSolutions by 3.6% during the third quarter. Nisa Investment Advisors LLC now owns 30,220 shares of the biopharmaceutical company’s stock valued at $3,123,000 after purchasing an additional 1,050 shares during the last quarter. Wells Fargo & Company MN raised its holdings in Emergent BioSolutions by 30.1% during the third quarter. Wells Fargo & Company MN now owns 607,711 shares of the biopharmaceutical company’s stock valued at $62,793,000 after buying an additional 140,558 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in Emergent BioSolutions during the third quarter valued at about $2,025,000. Finally, Pacer Advisors Inc. raised its holdings in Emergent BioSolutions by 22,967.3% during the third quarter. Pacer Advisors Inc. now owns 11,995 shares of the biopharmaceutical company’s stock valued at $1,239,000 after buying an additional 11,943 shares in the last quarter. 73.00% of the stock is owned by hedge funds and other institutional investors.

EBS stock traded up $4.27 during trading on Wednesday, reaching $107.65. 769,587 shares of the stock were exchanged, compared to its average volume of 522,511. Emergent BioSolutions Inc. has a twelve month low of $46.37 and a twelve month high of $137.61. The company has a market capitalization of $5.71 billion, a P/E ratio of 35.23 and a beta of 1.24. The stock has a 50 day simple moving average of $89.43 and a 200-day simple moving average of $98.22. The company has a current ratio of 3.20, a quick ratio of 2.30 and a debt-to-equity ratio of 0.68.

Emergent BioSolutions (NYSE:EBS) last released its earnings results on Wednesday, November 11th. The biopharmaceutical company reported $2.19 earnings per share for the quarter, topping analysts’ consensus estimates of $2.12 by $0.07. Emergent BioSolutions had a return on equity of 26.68% and a net margin of 12.50%. The business had revenue of $385.20 million for the quarter, compared to the consensus estimate of $438.51 million. During the same period last year, the business earned $1.24 earnings per share. The firm’s revenue for the quarter was up 23.5% compared to the same quarter last year. Equities analysts predict that Emergent BioSolutions Inc. will post 6.87 EPS for the current year.

Several equities analysts have weighed in on the company. Wells Fargo & Company lowered Emergent BioSolutions from an “overweight” rating to an “equal weight” rating and set a $110.00 target price on the stock. in a report on Friday, January 8th. Zacks Investment Research lowered Emergent BioSolutions from a “strong-buy” rating to a “hold” rating and set a $92.00 target price on the stock. in a report on Wednesday, November 11th. BidaskClub lowered Emergent BioSolutions from a “buy” rating to a “hold” rating in a report on Tuesday, December 29th. Finally, ValuEngine lowered Emergent BioSolutions from a “sell” rating to a “strong sell” rating in a report on Monday, November 9th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $95.43.

In other Emergent BioSolutions news, Chairman Fuad El-Hibri sold 20,000 shares of Emergent BioSolutions stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $90.44, for a total transaction of $1,808,800.00. Following the sale, the chairman now directly owns 1,143,988 shares of the company’s stock, valued at $103,462,274.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.10% of the stock is currently owned by insiders.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Recommended Story: What is the quiet period?

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent BioSolutions Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent BioSolutions (NYSE:EBS)

Receive News & Ratings for Emergent BioSolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent BioSolutions and related companies with MarketBeat.com's FREE daily email newsletter.